9/11 Uterine Cancer Lawyers: Endometrial Cancer VCF Compensation
Is Uterine Cancer covered by the 9/11 Victim Compensation Fund?
Yes. Uterine cancer, most commonly endometrial adenocarcinoma, is a covered condition under the WTC Health Program and eligible for compensation from the September 11th Victim Compensation Fund once certified. A diagnosis linked to 9/11 exposure can qualify for a VCF payout of up to $250,000, plus economic loss and, in fatal cases, wrongful death compensation.
Check Your 9/11 Claim Eligibility →Key Takeaways
- Eligibility: Presence in Lower Manhattan (south of Houston Street for WTC Health Program care, south of Canal Street for VCF compensation), at the Pentagon, or in Shanksville during the covered periods. See the complete 9/11 eligibility rules.
- Certification: Must be certified as 9/11-related by the WTC Health Program, or the VCF Private Physician Process if an exception applies.
- Award: Up to $250,000, plus economic loss, and wrongful death compensation for surviving families.
- Latency Period: 4 years from exposure to diagnosis, the minimum for most solid cancers, including uterine cancer.
- Deadline: The VCF is authorized through October 1, 2090. While you generally have 2 years from WTC Health Program certification to register, registering early protects your rights.
- No upfront cost: Attorney fees are capped at 10% by federal statute.
Who qualifies for 9/11 uterine cancer compensation?
Anyone diagnosed with uterine cancer following presence in the covered 9/11 areas, at the Pentagon, or in Shanksville, Pennsylvania during the covered periods may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from a 9/11-related uterine cancer.
Free medical care runs through the WTC Health Program, which covers Manhattan south of Houston Street and any block in Brooklyn within 1.5 miles of the former World Trade Center site. Compensation runs through the VCF, which covers Manhattan south of Canal Street plus routes of debris removal.
If you were between Canal and Houston Street, you may still qualify for both. Daily life in Lower Manhattan rarely stopped at Canal Street, and presence can be established with records or sworn affidavits.
Endometrial cancer, the most common form of uterine cancer, was added to the WTC Health Program's list of covered conditions effective January 18, 2023, later than many other cancers. Claimants who were told in the past that endometrial or uterine cancer was not covered should have their eligibility reassessed. Uterine sarcomas, a less common but more aggressive group, are certified separately, under the WTC Health Program's Rare Cancer policy.
What types of uterine cancer are covered by the WTC Health Program?
The WTC Health Program certifies uterine cancer under two different policies, both carrying the same four-year minimum latency.
- Endometrial adenocarcinoma: the most common form of uterine cancer, arising in the lining of the uterus, certified under the Program's 2023 Endometrial Cancer coverage determination.
- Endometrial intraepithelial neoplasia (EIN): a precancerous lesion, also called atypical endometrial hyperplasia, certified under that same 2023 determination given its significant risk of progressing to invasive cancer.
- Uterine carcinosarcoma, uterine leiomyosarcoma, and endometrial stromal sarcoma: less common, more aggressive uterine cancer subtypes, certified under the WTC Health Program's Rare Cancer policy.
Cervical cancer is not covered under either category. Invasive cervical cancer is certified separately, also as a rare cancer. Benign endometrial conditions, including endometrial polyps, ordinary hyperplasia without atypia, and uterine fibroids, are not covered by the WTC Health Program.
How did 9/11 exposure cause uterine cancer?
More than 400,000 people are estimated to have been exposed to 9/11 toxins across the covered areas in New York City, the Pentagon, and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens, including dioxins and polychlorinated biphenyls, substances studied for hormonal and endocrine-disrupting effects relevant to uterine and other reproductive cancers.
Women who worked, lived, or attended school in the affected area, including office workers, residents, first responders, and cleanup and recovery workers, faced sustained exposure to this contaminant mixture in the months following the attacks.
Certification does not require proof that 9/11 exposure was the only cause of a particular uterine cancer. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition, not whether it was the sole or exclusive cause.
Obesity, diabetes, hormone-related conditions, and family history are common, independently recognized risk factors for uterine cancer. Having one or more of these risk factors does not prevent certification of a 9/11-related uterine cancer claim.
What are the symptoms of 9/11-related uterine cancer?
The most common early symptom of uterine cancer is abnormal uterine bleeding, particularly bleeding after menopause. Other symptoms can include:
- Vaginal bleeding or spotting between periods, or after menopause
- Abnormal, watery, or blood-tinged vaginal discharge
- Pelvic pain or pressure
- Pain during intercourse
- Unexplained weight loss, more common with advanced disease
Postmenopausal bleeding is never normal and should always be evaluated promptly. Any of these symptoms in a person with 9/11 exposure history should be evaluated by a WTCHP participating specialist. The diagnosis itself can be made by any qualified physician, but certification of the cancer as being 9/11-related is made by the WTCHP.
What is the latency period for 9/11 uterine cancer?
Minimum latency4 years (uterine and endometrial cancers)
Uterine cancer's minimum latency period is 4 years between first 9/11 exposure and first diagnosis, the standard minimum the WTC Health Program applies to most solid cancers. This latency requirement is set by the WTC Health Program and has no exceptions.
Given that more than two decades have passed since September 11, 2001, nearly every claimant's uterine cancer diagnosis, whenever it occurred, satisfies the four-year minimum latency on its own.
By comparison, blood cancers have a minimum latency of just 0.4 years (146 days), thyroid cancer's minimum is 2.5 years, and mesothelioma has the longest latency under the program, at 11 years. Uterine cancer falls in the standard four-year group alongside most other solid tumors.
The two-year VCF registration deadline runs from the date the WTC Health Program certifies the uterine cancer as 9/11-related, not from the date of diagnosis. A uterine cancer diagnosed years ago, including before the January 2023 coverage date, remains eligible for certification and compensation review if registration is completed within the applicable two-year window.
What is the VCF payout for 9/11 uterine cancer?
Certified 9/11 uterine cancer qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss award for uterine cancer is published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.
Baseline non-economic loss award
- Uterine cancer baseline: $250,000. Endometrial adenocarcinoma, uterine carcinosarcoma, uterine leiomyosarcoma, and other covered uterine cancers are compensated at the statutory maximum of $250,000 for a single cancer condition, consistent with the VCF's treatment of solid cancers generally.
- Documentation supporting the baseline. The $250,000 baseline applies with medical documentation of the diagnosis and treatment. Hysterectomy, radiation, chemotherapy, or metastatic spread all support the baseline award, though advanced staging is not required to reach it.
Aggregate compensation with multiple certified conditions
Non-economic loss compensation for a single cancer condition is capped at $250,000 under the VCF Act. Where a claimant has multiple certified conditions on their own record, aggregate non-economic loss may exceed the $250,000 single-condition cap.
For a claimant with two or more certified cancers, aggregate non-economic loss compensation generally reaches at least $300,000. The current VCF aggregate maximum of $340,000 is reserved for claims involving multiple certified cancers, or a certified cancer alongside another certified condition of extraordinary severity. The $340,000 aggregate is not simply the sum of baseline amounts for each condition; the VCF weighs the severity of each certified condition together in setting the total award.
Economic loss, wrongful death, and expedited claims
In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts from uterine cancer treatment, including time missed for surgery or recovery. Wrongful death compensation is available to the personal representatives of individuals who died from a 9/11-related uterine cancer.
Uterine cancer is not one of the three conditions the VCF treats as automatically, presumptively terminal for expedited claim processing. When an advanced uterine cancer, such as carcinosarcoma, has reached an imminently terminal stage, a claim can still qualify for expedited VCF review under the fund's general terminal illness pathway, which requires a treating physician's documentation of prognosis. Attorney fees for VCF claims are capped at 10% by federal statute.
How Baione Law handles a 9/11 uterine cancer claim
Baione Law represents 9/11 uterine cancer claimants at every stage:
- Free Case Review. The firm evaluates presence in the exposure zone, exposure category, uterine cancer diagnosis, subtype, and current WTCHP certification status. No cost, no obligation.
- WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates medical record submission to WTCHP providers for certification.
- VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, pathology, staging, and treatment history.
- Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires.
- Award, appeals, and amendments. After the VCF issues an award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions or documented progression of the uterine cancer.
Attorney fees are capped at 10% by federal statute.
Common questions
The baseline non-economic loss award for uterine cancer, including endometrial adenocarcinoma and uterine carcinosarcoma, is $250,000, the statutory maximum for a single cancer condition. The exceptions to this baseline are non-melanoma skin cancer, which baselines at $90,000, and prostate cancer, which baselines at $200,000.
For claimants with two or more certified cancers, aggregate non-economic loss compensation generally reaches $300,000. The VCF aggregate maximum of $340,000 is reserved for claims involving certified cancer(s) alongside another certified condition of extraordinary severity. Economic loss compensation for medical expenses and lost earnings, and wrongful death compensation, may be available in addition.
No. Cervical cancer is certified separately from uterine cancer, under the WTC Health Program's rare-cancer framework, and only invasive cervical cancer is covered. Non-invasive cervical conditions are not eligible for certification. If you have a cervical cancer diagnosis rather than a uterine or endometrial cancer diagnosis, ask about certification under the rare-cancer category specifically.
Yes. Endometrial cancer became a covered condition effective January 18, 2023, but that date governs when the WTC Health Program began certifying the condition, not which diagnoses qualify. An endometrial cancer diagnosed years before 2023 can still be certified and compensated if it meets the latency and exposure requirements. Uterine sarcomas are certified under the separate Rare Cancer policy and are not affected by the 2023 date at all.
Uterine cancer is not one of the three conditions the VCF automatically treats as presumptively terminal for expedited processing (glioblastoma, pancreatic adenocarcinoma, and acute erythrocytic leukemia). If a uterine cancer, such as carcinosarcoma, has progressed to an imminently terminal stage, a claim can still qualify for expedited review under the VCF's general terminal illness pathway.
That pathway requires medical documentation from a treating physician establishing prognosis and life expectancy. A diagnosis described as metastatic or stage IV alone does not establish that a condition is imminently terminal; the VCF considers the full medical picture. See our guide to expedited VCF claims for the specific documentation each pathway requires.
Prior diagnoses from years earlier may still be eligible for VCF compensation. The two-year VCF registration deadline runs from the date the WTC Health Program certifies the uterine cancer as 9/11-related, not from the date of diagnosis.
Registration preserves the right to file a claim; the claim filing deadline is October 1, 2090 for all claimants. A uterine cancer diagnosed in 2005, 2010, 2015, 2020, or today may still qualify if certification occurs and the claim is approved for eligibility.
Yes. The VCF accepts wrongful death claims from the personal representatives of individuals who died from a 9/11-related uterine cancer. Presence, exposure, medical records of the diagnosis or WTCHP certification of the uterine cancer, and specific documentation of cause of death are required.
September 17, 2026 · Based on Public Health Service Act §3312(a)(1)(A) (42 U.S.C. §300mm-22), 42 C.F.R. §§88.1, 88.15, and 88.17, WTC Health Program Administrative Manual (including Special Note on Malignancy for Cancers), WTC Health Program Administrator, Minimum Latency & Types or Categories of Cancer policy, WTC Health Program Medical Coverage Determination, Endometrial Cancer and Endometrial Intraepithelial Neoplasia (Uterine Cancer), published January 18, 2023, WTC Health Program Policy and Procedure, Rare Cancer, effective May 5, 2014, VCF Policies & Procedures Section 2.1 effective August 19, 2026, VCF Non-Economic Loss Awards and Certified Conditions Fact Sheet, VCF 2025 Annual Report, American Cancer Society reference pages on uterine and endometrial cancer. Figures and deadlines may change — confirm the details that apply to your claim.
Get Your Free Case Review
Diagnosed with uterine cancer? Our attorneys will evaluate your situation at no cost. All consultations are confidential and covered by attorney-client privilege. Attorney fees are capped at 10% by federal statute.